2020201920182017201620152014 July 16, 2019 Summary ToggleSpero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206 June 28, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 20, 2019 Summary ToggleSpero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis June 17, 2019 Summary ToggleSpero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference June 13, 2019 Summary ToggleSpero Announces $10 Million Registered Direct Offering of Common Stock May 31, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 09, 2019 Summary ToggleSpero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review May 01, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 08, 2019 Summary ToggleSpero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases March 29, 2019 Summary ToggleSpero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
